J-REGISTER: real-world study of Japanese patients with <i>EGFR</i> mutation-positive NSCLC treated with first-line afatinib.

ABSTRACT:

Aim

The J-REGISTER study assessed outcomes and subsequent treatment in patients with EGFR mutation-positive NSCLC treated with first-line afatinib, including patients with uncommon EGFR mutations.

Patients & methods

This retrospective study assessed 805 patients treated with afatinib in Japan. The primary objective was time on treatment with afatinib. Other objectives included time on treatment from initiation of afatinib until the end of second-line therapy, and overall survival.

Results

Median time on treatment with afatinib was 13.4 months (14.3/10.1 months in patients with common/uncommon mutations). Median overall time on treatment was highest in patients who received sequential afatinib and osimertinib (32.8 months). Median overall survival was 41.

SUBMITTER: Yamaguchi T 

PROVIDER: S-EPMC12218542 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature